Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients

Conclusion: 225Ac-PSMA-617 TAT showed promising disease control rate, even when all other therapeutic options were exhausted, with low treatment-related toxicities.

Source: Theranostics - October 3, 2020 Category: Molecular Biology Authors: Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Madhavi Tripathi, Amlesh Seth, Chandrasekhar Bal Tags: Research Paper Source Type: research